Business Context and Reporting Period
This Form 6-K is filed by Oncolytics Biotech Inc., a foreign private issuer, for the month of August 2014. The filing date is August 8, 2014. The primary purpose of this report is to incorporate by reference specific exhibits into the company's Registration Statement on Form F-10 (File No. 333-197633).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a procedural filing to attach legal agreements rather than a financial results report.
Material Changes
The material event disclosed is the execution of an Amendment to a Purchase Agreement with Lincoln Park Capital Fund, LLC, dated August 8, 2014. This amendment is filed as Exhibit 99.3. The filing also references a prior Purchase Agreement and Placement Agent Agreement from February 27, 2014, which are incorporated by reference.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. The document focuses solely on the incorporation of legal exhibits related to the company's capital raising activities.
Key Facts for Investor Verification
- Verify the specific terms of the Amendment to the Purchase Agreement with Lincoln Park Capital Fund, LLC (Exhibit 99.3) to understand changes to the original February 2014 agreement.
- Review the Registration Statement on Form F-10 (File No. 333-197633) to see how these exhibits impact the company's capital structure.
- Note that this filing contains no operational or financial performance data for the period.